Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28940951 | 0.97 | CYP1A2 (0.56) | CYP1A2TDP1HSD11B1HTR1APOLB | |
| Hydrochloric Acid SCHEMBL321914 | 0.97 | CYP1A2 (0.56) | CYP1A2TDP1HSD11B1HTR1APOLB | |
| Hydrochloric Acid SCHEMBL23491424 | 0.95 | CYP1A2 (0.54) | CYP1A2TDP1HSD11B1HTR1APOLB | |
| SCHEMBL23199864 | 0.91 | HTT (0.55) | CYP1A2TDP1HSD11B1HTR1APOLB | |
| Hydrochloric Acid SCHEMBL28031922 | 0.87 | CYP1A2 (0.46) | CYP1A2TDP1HSD11B1HTR1APOLB | |
| SCHEMBL9737159 | 0.85 | ALDH1A1 (0.40) | CYP1A2TDP1POLBHTTKMT2A | |
| SCHEMBL26287179 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL11450245 | 0.82 | ALDH1A1 (0.38) | CYP1A2TDP1POLBHTTKMT2A | |
| SCHEMBL1203272 | 0.78 | CYP1A2 (0.59) | CYP1A2TDP1POLBEPHX2KMT2A | |
| Hydrochloric Acid SCHEMBL30491041 | 0.77 | L3MBTL3 (0.49) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1029 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113529199-B | Flame-retardant nano SiO 2 Synthesis method of super-molecular weight polyethylene puncture-proof fiber | 瑞安市博安防刺穿材料科技有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-111171034-B | Preparation method of zopiclone intermediate | 四川弘远药业有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-113529199-A | Flame-retardant nano SiO2Synthesis method of-supermolecule polyethylene puncture-proof fiber | 瑞安市博安防刺穿材料科技有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-111171034-A | Preparation method of zopiclone intermediate | 成都弘达药业有限公司 | 2020-05-19 | — | — | CN | claimed |
| CN-102050802-B | N-(2-ethoxyl)ferulamide nitrate derivative with anoxia resisting pharmaceutical activity and preparation method thereof | XU JINGFENG | 2013-01-09 | — | — | CN | claimed |
| US-8309723-B2 | Preparation of Zopiclone and its enantiomerically enriched isomer | Mylan Laboratories Ltd. (IN) | 2012-11-13 | — | — | US | claimed |
| CN-102050802-A | N-(2-ethoxyl)ferulamide nitrate derivative with anoxia resisting pharmaceutical activity and preparation method thereof | JINGFENG XU | 2011-05-11 | — | — | CN | claimed |
| US-20100056785-A1 | Preparation Of Zopiclone And Its Enantiomerically Enriched Isomer | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2010-03-04 | — | — | US | claimed |
| WO-2009101634-A2 | A NOVEL PROCESS FOR THE PREPARATION OF ESZOPICLONE | LUPIN LIMITED (IN) | 2009-08-20 | — | — | WO | claimed |
| WO-2008126105-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ZOPICLONE AND IT'S ENANTIOMERICALLY ENRICHED ISOMER | MATRIX LABORATORIES LTD (IN) | 2008-10-23 | — | — | WO | claimed |
| EP-1904499-A1 | PROCESS FOR THE PREPARATION OF ZOPICLONE | Teva Pharmaceutical Industries Ltd (IL) | 2008-04-02 | — | — | EP | claimed |
| US-20080015197-A1 | Process for the preparatrion of zopiclone | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | claimed |
| WO-2008002629-A1 | PROCESS FOR THE PREPARATION OF ZOPICLONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-03 | — | — | WO | claimed |
| JP-1071865-A | — | — | None | — | — | JP | disclosed |
| CN-119371356-B | Nuciferine derivative, and preparation method and application thereof | 云南中医药大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-122029153-A | Aromatic hydrocarbon receptor modulator compound, and preparation method and application thereof | 德明药泰生物技术（深圳）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-4016274-A | TRANQUILIZERS AND ANTICONVULSANT AGENTS | RHONE-POULENC S.A. (FR) | 1977-04-05 | — | — | US | disclosed |
| US-4002641-A | DIURETICS, SALURETICS, HYPOTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
| US-3966931-A | TRANQUILIZERS, ANTICONVULSANTS, HYPNOSIS | RHONE-POULENC S.A. (FR) | 1976-06-29 | — | — | US | disclosed |
| US-3948917-A | TRANQUILIZERS, ANTICONVULSANTS, DECONTRACTURANTS, HYPNOSIS | RHONE-POULENC S.A. (FR) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015197-A1 | Process for the preparatrion of zopiclone | CYP3A5, CYP3A7, CYP3A43 | CYP1A2 18/4885TDP1 4651/4885HSD11B1 45/4885 |
| US-20100056785-A1 | Preparation Of Zopiclone And Its Enantiomerically Enriched Isomer | CYP3A5, CYP4Z1, FZD7 | CYP1A2 114/4885TDP1 4546/4885HSD11B1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.